Ultragenyx Pharmaceutical Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ultragenyx Pharmaceutical Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-15.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 55% of Healthcare companies in United States.
Cash Locked Ratio
$27For every $100 of sales, $27 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $7 tied up three years earlier.
More money tied up than 57% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$43Sales grew 85% in 3 years; of every extra $100 of sales, $43 became extra profit.
Higher than 66% of Healthcare companies in United States.
Asset Productivity Ratio
+85% / -1%In 3 years sales changed by +85% while total assets changed by -1%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-38.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 67% of Healthcare companies in United States.
Cash Cushion Ratio
+41%Cash, after subtracting all debt, equals 41% of its market value (net cash).
Higher than 74% of Healthcare companies in United States.
Tangible Assets Ratio
86%Of every $100 the company owns, $86 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 56% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Ultragenyx Pharmaceutical Inc. made a loss over the last year. Ultragenyx Pharmaceutical Inc. owes $1.22 for every $1 it owns. Ultragenyx Pharmaceutical Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossUltragenyx Pharmaceutical Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-5.40Ultragenyx Pharmaceutical Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1.6 BThe total market value of all of Ultragenyx Pharmaceutical Inc.'s shares at today's price (share price × number of shares), larger than 70% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeUltragenyx Pharmaceutical Inc.'s net worth is negative ($291 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.22×Ultragenyx Pharmaceutical Inc. owes $1.22 for every $1 it owns, so it owes more than it owns, higher than 92% of Healthcare companies in United States.
Dividend yield
NoneUltragenyx Pharmaceutical Inc. does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Profit growth
LossUltragenyx Pharmaceutical Inc. made a loss in each of the last two years.
Profit margin
-85.4%Ultragenyx Pharmaceutical Inc. lost $85 for every $100 of revenue.
Interest cover
Not coveredUltragenyx Pharmaceutical Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashUltragenyx Pharmaceutical Inc. held $644 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Ultragenyx Pharmaceutical Inc. owe compared with what it owns?
Ultragenyx Pharmaceutical Inc. owes $1.22 for every $1 it owns, so it owes more than it owns, higher than 92% of Healthcare companies in United States.
Does Ultragenyx Pharmaceutical Inc. pay a dividend?
No. Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.
Is Ultragenyx Pharmaceutical Inc.'s revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 23% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.